lifestyle.longislandreport.org

Author: Mylan Inc.

Viatris to Report First Quarter 2026 Financial Results on May 7, 2026

April 13, 2026
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

April 10, 2026
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

March 23, 2026
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

March 19, 2026
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

February 26, 2026
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

February 26, 2026
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

February 25, 2026
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

February 3, 2026
Viatris Appoints Matthew J. Maletta as Chief Legal Officer

February 3, 2026
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company’s First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

January 23, 2026